Published on 9 May 2024 on Simply Wall St. via Yahoo Finance
Analysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) defied analyst predictions to release its first-quarter results, which were ahead of market expectations. Revenues beat expectations coming in atUS$93m, ahead of estimates by 8.5%. Statutory losses were somewhat smaller thanthe analysts expected, coming in at US$0.17 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
Check out our latest analysis for BioCryst Pharmaceuticals
